The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review

References

• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi:10.1164/rccm.201204-0596PP.
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016. [cited 2016 Apr 16]. Available from: http://goldcopd.org/.
   Google Scholar
• Soriano JB, Lamprecht B, Ramírez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015;3:443–450. doi:10.1016/S2213-2600(15)00157-5.
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Gaga M, et al. Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets. 2013;14:192–224. doi:10.2174/1389450111314020006.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636–645. doi:10.1016/j.jaci.2012.12.1564.
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750.
   PubMed Web of Science ®Google Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106:989–997. doi:10.1016/j.rmed.2012.03.008.
   PubMed Web of Science ®Google Scholar
• Roche N, Pribil C, Van Ganse E, et al. Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. BMC Pulm Med. 2014;14:56. doi:10.1186/1471-2466-14-56.
   PubMed Web of Science ®Google Scholar
• Worth H, Buhl R, Criée CP, et al. The ‘real-life’ COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64–71. doi:10.1016/j.rmed.2015.12.010.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S91694.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Macagno F, Valente S, et al. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem. 2013;20:1464–1476. doi:10.2174/0929867311320120002.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58:4131–4164. doi:10.1021/jm5013227.
   PubMed Web of Science ®Google Scholar
• Lacasse Y, Cates CJ, McCarthy B, et al. This Cochrane Review is closed: deciding what constitutes enough research and where next for pulmonary rehabilitation in COPD. Cochrane Database Syst Rev. 2015;11:ED000107. doi:10.1002/14651858.ED000107.
   Google Scholar
• Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844. doi:10.1002/14651858.CD010844.pub2.
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991. doi:10.1002/14651858.CD002991.pub3.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015 Oct 26;5(10):e009183. doi:10.1136/bmjopen-2015-009183.
   PubMed Web of Science ®Google Scholar
• Roche N, Marthan R, Berger P, et al. Beyond corticosteroids: future prospects in the management of inflammation in COPD. Eur Respir Rev. 2011;20:175–182. doi:10.1183/09059180.00004211.
   PubMedGoogle Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419. doi:10.1183/13993003.01359-2015.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006;4:253–262. doi:10.1370/afm.517.
   PubMed Web of Science ®Google Scholar
• Karbasi-Afshar R, Aslani J, Ghanei M. Efficacy and safety of inhaler steroids in COPD patients: systematic review and meta-analysis of randomized placebo-controlled trials. Caspian J Intern Med. 2014;5:130–136.
   PubMedGoogle Scholar
• Spencer S, Karner C, Cates CJ, et al. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007033. doi:10.2174/0929867311320120003.
   Google Scholar
• Kew KM. Seniukovich A.Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115. doi:10.1002/14651858.CD010115.pub2.
   PubMed Web of Science ®Google Scholar
• Weatherall M, Clay J, James K, et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14:983–990. doi:10.1111/j.1440-1843.2009.01589.x.
   PubMed Web of Science ®Google Scholar
• Stockley RA. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin. 2009;25:1235–1245. doi:10.1185/03007990902868971.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543–559. doi:10.1038/nrd4025.
   PubMed Web of Science ®Google Scholar
• Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect. 1985;64:111–126. doi:10.2307/3430003.
   PubMed Web of Science ®Google Scholar
• King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015;4:26. doi:10.1186/s40169-015-0068-z.
   Google Scholar
• Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 2002;283:L867–73. doi:10.1152/ajplung.00020.2002.
   PubMed Web of Science ®Google Scholar
• Berenson CS, Kruzel RL, Eberhardt E, et al. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis. 2013;208:2036–2045. doi:10.1093/infdis/jit400.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:349–355. doi:10.1164/ajrccm.163.2.2003122.
   PubMed Web of Science ®Google Scholar
• Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9:377–384. doi:10.1038/nri2530.
   PubMed Web of Science ®Google Scholar
• Prins HJ, Daniels JM, Lindeman JH, et al. Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial. Respir Med. 2016;110:46–52. doi:10.1016/j.rmed.2015.10.009.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Aquino TO, O’Brien CD, et al. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. Copd. 2012;9:111–120. doi:10.3109/15412555.2011.641803.
   PubMedGoogle Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672–688. doi:10.1183/09031936.03.00040703.
   PubMed Web of Science ®Google Scholar
• Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:2445–2454. doi:10.1056/NEJMra0804752.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Demoor T, Bracke KR, et al. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J. 2009;34:219–230. doi:10.1183/09031936.00150208.
   PubMed Web of Science ®Google Scholar
• Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:1179–1188. doi:10.1164/rccm.200904-0552OC.
   PubMed Web of Science ®Google Scholar
• Sirianni FE, Chu FS, Walker DC. Human alveolar wall fibroblasts directly link epithelial type 2 cells to capillary endothelium. Am J Respir Crit Care Med. 2003;168:1532–1537. doi:10.1164/rccm.200303-371OC.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Yoshida T, Arap W, et al. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc. 2006;3:503–510. doi:10.1513/pats.200603-054MS.
   PubMedGoogle Scholar
• Shaykhiev R, Sackrowitz R, Fukui T, et al. Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancer. Am J Respir Cell Mol Biol. 2013;49:418–425. doi:10.1165/rcmb.2012-0396OC.
   PubMed Web of Science ®Google Scholar
• Angelis N, Porpodis K, Zarogoulidis P, et al. Airway inflammation in chronic obstructive pulmonary disease. J Thorac Dis. 2014;6:S167–72. doi:10.3978/j.issn.2072-1439.2014.03.07.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today. 2011;16:1084–1091. doi:10.1016/j.drudis.2011.09.005.
   PubMed Web of Science ®Google Scholar
• Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20:1477–1495. doi:10.2174/0929867311320120003.
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM. Inhaled steroids in COPD: when should they be used? Lancet Respir Med. 2014;2:869–871. doi:10.1016/S2213-2600(14)70227-9.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa063070.
   PubMed Web of Science ®Google Scholar
• Gunen H, Hacievliyagil SS, Yetkin O, et al. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29:660–667. doi:10.1183/09031936.00073506.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285–1294. doi:10.1056/NEJMoa1407154.
   PubMed Web of Science ®Google Scholar
• Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8:93. doi:10.1186/1465-9921-8-93.
   PubMed Web of Science ®Google Scholar
• Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. The Lancet. 2009;374:670–672. doi:10.1016/S0140-6736(09)61541-5.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellance. NICE guideline chronic obstructive pulmonary disease CG101: Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. [ cited 2016 Apr 16]. Available from: https://www.nice.org.uk/guidance/cg101.
   Google Scholar
• Montuschi P, Malerba M, Santini G, et al. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014;19:1928–1935. doi:10.1016/j.drudis.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid effects on cell signaling. Eur Respir J. 2006;27:413–426. doi:10.1183/09031936.06.00125404.
   PubMed Web of Science ®Google Scholar
• Currie GP, Lipworth BJ. Inhaled treatment for chronic obstructive pulmonary disease: what’s new and how does it fit? QJM. 2015;1–8. doi:10.1093/qjmed/hcv212.
   PubMedGoogle Scholar
• D’Urzo A, Donohue JF, Kardos P, et al. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015;16:1845–1860. doi:10.1517/14656566.2015.1067682.
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698–702. doi:10.1183/09031936.04.00121404.
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS, et al. Inhaled steroids in obstructive lung disease in Europe study investigators. Eur Respir J. 2003;21:68–73. doi:10.1183/09031936.03.00013303.
   PubMed Web of Science ®Google Scholar
• Van Der Valk P, Monninkhof E, Van Der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358–1363. doi:10.1164/rccm.200206-512OC.
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81. doi:10.1183/09031936.03.00031402.
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–537. doi:10.1183/09031936.00128914.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719–725. doi:10.1136/thx.2010.136077.
   PubMed Web of Science ®Google Scholar
• Malerba M, Montuschi P, Radaeli A, et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today. 2015;20:129–135. doi:10.1016/j.drudis.2014.09.005.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Thorlund K, Ioannidis JPA. Demystifying trial networks and network meta-analysis. BMJ. 2013;346:f2914. doi:10.1136/bmj.f2914.
   PubMed Web of Science ®Google Scholar
• Tattersfield AE, Harrison TW, Hubbard RB, et al. Safety of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:171–175. doi:10.1513/pats.200402-016MS.
   PubMedGoogle Scholar
• Molimard M, Girodet PO, Pollet C, et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf. 2008;31:769–774. doi:10.2165/00002018-200831090-00005.
   PubMed Web of Science ®Google Scholar
• Chee C, Sellahewa L, Pappachan JM. Inhaled corticosteroids and bone health. Open Respir Med J. 2014;8:85–92. doi:10.2174/1874306401408010085.
   PubMedGoogle Scholar
• Garbe E, LeLorier J, Boivin JF, et al. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350:979–982. doi:10.1016/S0140-6736(97)03392-8.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Murray HE, Skeans M, et al. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004;126:1123–1133. doi:10.1378/chest.126.4.1123.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cardaci V, Cazzola M, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14:533–541. doi:10.1517/14740338.2015.1001363.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189–195. doi:10.2147/COPD.S6942.
   PubMedGoogle Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–1036. doi:10.1136/thoraxjnl-2012-202872.
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12:27–34. doi:10.1513/AnnalsATS.201409-413OC.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest. 2009;136:1456–1465. doi:10.1378/chest.08-3016.
   PubMed Web of Science ®Google Scholar
• Gonzalez AV, Li G, Suissa S, et al. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther. 2010;23:65–70. doi:10.1016/j.pupt.2009.10.014.
   PubMed Web of Science ®Google Scholar
• Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010;35:1003–1021. doi:10.1183/09031936.00095909.
   PubMed Web of Science ®Google Scholar
• Suissa S. Will SUMMIT reach the peak in COPD? Thorax. 2014;69:405–407. doi:10.1136/thoraxjnl-2014-205203.
   PubMed Web of Science ®Google Scholar
• Royce SG, Karagiannis TC. Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions. Curr Opin Allergy Clin Immunol. 2014;14:44–48. doi:10.1097/ACI.0000000000000029.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol. 2009;71:451–464. doi:10.1146/annurev.physiol.010908.163257.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest. 2006;129:151–155. doi:10.1378/chest.129.1.151.
   PubMed Web of Science ®Google Scholar
• Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kB suppression. J Exp Med. 2006;203:7–13. doi:10.1084/jem.20050466.
   PubMed Web of Science ®Google Scholar
• Snoeck-Stroband JB, Lapperre TS, Sterk PJ, et al. Prediction of long-term benefits of inhaled steroids by phenotypic markers in moderate-to-severe COPD: a randomized controlled trial. PLoS One. 2015;10:e0143793. doi:10.1371/journal.pone.0143793.
   Google Scholar
• Pujols L, Mullol J, Picado C. Importance of glucocorticoid receptors in upper and lower airways. Front Biosci (Landmark Ed). 2010;15:789–800. doi:10.2741/3646.
   PubMed Web of Science ®Google Scholar
• Li LB, Leung DY, Martin RJ, et al. Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor beta in steroid-resistant asthma. Am J Respir Crit Care Med. 2010;182:877–883. doi:10.1164/rccm.201001-0015OC.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866. doi:10.1016/S0140-6736(14)62410-7.
   PubMed Web of Science ®Google Scholar
• Roversi S, Tonelli R, Fabbri LM. Breakthroughs in internal and respiratory medicine. Lancet Respir Med. 2015;3:600–602. doi:10.1016/S2213-2600(15)00251-9.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703. doi:10.1016/S0140-6736(09)61252-6.
   PubMed Web of Science ®Google Scholar
• Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134:314–322. doi:10.1016/j.jaci.2014.02.001.
   PubMed Web of Science ®Google Scholar
• Milara J, Morell A, Ballester B, et al. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir Res. 2015;16:12. doi:10.1186/s12931-015-0179-5.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention 2015. [ cited 2015 Apr 16]. Available from http://www.ginasthma.org/.
   Google Scholar
• Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD Overlap Syndrome (ACOS): a systematic review and meta analysis. PLoS One. 2015;10:e0136065. doi:10.1371/journal.pone.0136065.
   PubMed Web of Science ®Google Scholar
• Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013;6:197–219. doi:10.1586/ecp.13.2.
   PubMed Web of Science ®Google Scholar
• Van Den Berge M, Aalbers R. He asthma-COPD overlap syndrome: how is it defined and what are its clinical implications? J Asthma Allergy. 2016;9:27–35. doi:10.2147/JAA.S78900.
   PubMedGoogle Scholar
• Travers J, Marsh S, Shirtcliffe P, et al. External validity of pharmaceutical trials in asthma and chronic obstructive pulmonary disease. In: Rothwell PM, editors. Treating individuals: from randomised trials to personalised medicine. Oxford: Elsevier; 2007. p. 131–135.
   Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008 Nov;24(11):3063–3072. doi:10.1185/03007990802457040.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385:1789–1798. doi:10.1016/S0140-6736(15)60693-6.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J. 2013 Mar;22(1):117–121. doi:10.4104/pcrj.2013.00016.
   PubMedGoogle Scholar
• Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158:1511–1517. doi:10.1164/ajrccm.158.5.9804028.
   PubMed Web of Science ®Google Scholar
• Loukides S, Bartziokas K, Vestbo J, et al. Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. Curr Drug Targets. 2013;14:235–245. doi:10.2174/1389450111314020008.
   PubMed Web of Science ®Google Scholar